{"id":41551,"date":"2025-09-16T16:39:46","date_gmt":"2025-09-16T08:39:46","guid":{"rendered":"https:\/\/flcube.com\/?p=41551"},"modified":"2025-09-16T16:39:47","modified_gmt":"2025-09-16T08:39:47","slug":"monte-rosa-therapeutics-and-novartis-partner-on-degrader-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41551","title":{"rendered":"Monte Rosa Therapeutics and Novartis Partner on Degrader Development"},"content":{"rendered":"\n<p><strong>Monte Rosa Therapeutics, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GLUE:NASDAQ\">NASDAQ: GLUE<\/a>)<\/strong> announced today a new collaboration with <strong>Novartis<\/strong> <strong>(<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>)<\/strong> to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-collaboration-highlights\">Collaboration Highlights<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target\u2011Focused Degraders<\/strong> \u2013 The deal centers on highly credentialed, difficult\u2011to\u2011drug targets that drive immune\u2011mediated disorders.<\/li>\n\n\n\n<li><strong>Exclusive License<\/strong> \u2013 Novartis receives an exclusive license to one undisclosed discovery target, plus options to license two additional programs from Monte\u202fRosa\u2019s preclinical immunology pipeline.<\/li>\n\n\n\n<li><strong>AI\u2011Powered Discovery<\/strong> \u2013 Monte\u202fRosa will deploy its proprietary AI\/ML\u2011enabled <strong>QuEEN<\/strong> engine to identify and optimize degraders that Novartis will further develop and commercialize.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Value<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>USD\u202f120\u202fmillion<\/strong><\/td><td>Immediate cash to Monte\u202fRosa<\/td><\/tr><tr><td><strong>Option Maintenance<\/strong><\/td><td><strong>USD\u202f5.7\u202fbillion (total potential)<\/strong><\/td><td>Includes upfront, milestone, exercise, and sales\u2011based royalties<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Preclinical, development, regulatory, sales<\/td><td>Tiered royalties in the high single\u2011digit to low double\u2011digit range on global net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The maximum upside of <strong>USD\u202f5.7\u202fbillion<\/strong> underscores Novartis\u2019s confidence in Monte\u202fRosa\u2019s technology platform and the therapeutic potential of the target space.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development<\/strong> \u2013 By combining Novartis\u2019s clinical and commercial expertise with Monte\u202fRosa\u2019s degrader platform, the partnership is poised to shorten the path from discovery to market.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 The collaboration adds a new class of degraders to Novartis\u2019s immunology arm, diversifying its pipeline beyond conventional biologics and small molecules.<\/li>\n\n\n\n<li><strong>Technology Leadership<\/strong> \u2013 Monte\u202fRosa\u2019s AI\u2011driven QuEEN engine positions the company at the forefront of precision degrader design, potentially setting a new standard for target validation.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h4>\n\n\n\n<p>Monte\u202fRosa remains a key player in the burgeoning degrader landscape, and the partnership with Novartis is expected to unlock high\u2011impact therapies for patients with autoimmune and inflammatory diseases. The deal also signals confidence from a major pharma partner, likely attracting additional collaborations and investment into Monte\u202fRosa\u2019s growing portfolio.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1744,1743,140,865,70],"class_list":["post-41551","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-monte-rosa-therapeutics","tag-nasdaq-glue","tag-novartis","tag-nyse-nvs","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Monte Rosa Therapeutics and Novartis Partner on Degrader Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS) to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41551\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monte Rosa Therapeutics and Novartis Partner on Degrader Development\" \/>\n<meta property=\"og:description\" content=\"Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS) to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41551\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T08:39:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-16T08:39:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Monte Rosa Therapeutics and Novartis Partner on Degrader Development\",\"datePublished\":\"2025-09-16T08:39:46+00:00\",\"dateModified\":\"2025-09-16T08:39:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1605.webp\",\"keywords\":[\"Monte Rosa Therapeutics\",\"NASDAQ: GLUE\",\"Novartis\",\"NYSE: NVS\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41551#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41551\",\"name\":\"Monte Rosa Therapeutics and Novartis Partner on Degrader Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1605.webp\",\"datePublished\":\"2025-09-16T08:39:46+00:00\",\"dateModified\":\"2025-09-16T08:39:47+00:00\",\"description\":\"Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS) to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41551\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1605.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1605.webp\",\"width\":1080,\"height\":608,\"caption\":\"Monte\u202fRosa Therapeutics and Novartis Partner on Degrader Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41551#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monte Rosa Therapeutics and Novartis Partner on Degrader Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Monte Rosa Therapeutics and Novartis Partner on Degrader Development - Insight, China&#039;s Pharmaceutical Industry","description":"Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS) to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41551","og_locale":"en_US","og_type":"article","og_title":"Monte Rosa Therapeutics and Novartis Partner on Degrader Development","og_description":"Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS) to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.","og_url":"https:\/\/flcube.com\/?p=41551","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-16T08:39:46+00:00","article_modified_time":"2025-09-16T08:39:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41551#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41551"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Monte Rosa Therapeutics and Novartis Partner on Degrader Development","datePublished":"2025-09-16T08:39:46+00:00","dateModified":"2025-09-16T08:39:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41551"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41551#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp","keywords":["Monte Rosa Therapeutics","NASDAQ: GLUE","Novartis","NYSE: NVS","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41551#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41551","url":"https:\/\/flcube.com\/?p=41551","name":"Monte Rosa Therapeutics and Novartis Partner on Degrader Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41551#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41551#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp","datePublished":"2025-09-16T08:39:46+00:00","dateModified":"2025-09-16T08:39:47+00:00","description":"Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS) to develop next\u2011generation degraders for immune\u2011mediated diseases. This agreement follows Monte\u202fRosa\u2019s October\u202f2024 global exclusive license for its VAV1 degraders, including MRT\u20116160, and marks the company\u2019s second partnership with the Swiss pharmaceutical giant.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41551#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41551"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41551#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp","width":1080,"height":608,"caption":"Monte\u202fRosa Therapeutics and Novartis Partner on Degrader Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41551#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Monte Rosa Therapeutics and Novartis Partner on Degrader Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1605.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41551"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41551\/revisions"}],"predecessor-version":[{"id":41553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41551\/revisions\/41553"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41552"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}